Comparative Marker Assessment in Small Cell Lung Cancer with Good and Poor Prognosis Abstract #1162

Introduction: Small cell lung cancers (SCLC) are highly aggressive and poorly differentiated neuroendocrine neoplasms which comprise ̴̴̴15 % of all lung malignancies.
Aim(s): In a panel of patients with diagnosed SCLC with poor and good prognosis we investigated the prognostic impact by analyzing protein and mRNA expression levels of 9 molecular markers. Furthermore we studied the influence of therapeutic interventions on the prognosis.
Materials and methods: Formalin-fixed, paraffin-embedded tumor samples of 27 SCLC patients with good prognosis (survival ≥ 30 months) and 19 patients with poor prognosis (survival < 30 months) were analyzed for the receptors SSTR1, 2A, 3, 4, 5, CXCR4 and the proliferation markers Ki-67, TOP2A and RacGAP1 by means of immunohistochemistry and RT-qPCR.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Lydia Schmidt

To read results and conclusion, please login ...

Further abstracts you may be interested in

#833 The Chemokine Receptor CXCR4 – Differential Expression in Bronchopulmonary Neuroendocrine Neoplasms
Introduction: The CXCR4 is a plasma membrane chemokine receptor, which is involved in organogenesis, hematopoiesis and inflammation. Additionally, an over-expression is described for many neoplastic tissues. Here, an involvement in tumor progression, metastasis, adaptation to hypoxia and in stem cell survival is postulated.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: Christiane Anne Reimann
#3030 Targeting CXCR4 and Thioredoxin Reductase in Theranostics of Atypical Carcinoid and Neuroendocrine Carcinoma
Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dijie Liu
#3011 Added Prognostic Value of Molecular Imaging Biomarkers over Proliferation Index in Typical Lung Carcinoid: An FDG PET and SSTR Imaging Study
Introduction: Typical lung carcinoids(TCs)are rare tumors with good,although heterogeneous,prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD Vittorio Briganti
#877 Immunohistochemical and qRT-PCR-Based Evaluation of Somatostatin Receptor 1 to 5 Expression in 92 Patients with Bronchopulmonary Neuroendocrine Neoplasms
Introduction: Little is known about the somatostatin receptor (SSTR) status in bronchopulmonary neuroendocrine neoplasms (BP-NEN), comprising typical carcinoids (TC), atypical carcinoids (AC), small cell lung cancer (SCLC) and large cell neuroendocrine lung carcinomas (LCNEC).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Elisa Specht
#879 The Assessment of Proliferation in BP-NEN Entities Based on the Three Proliferation Markers Ki-67, TOP2A and RacGAP1
Introduction: The extent of cell proliferation as an important component of carcinogenesis can be detected in tumor tissues by means of various factors.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Elisa Specht